Informed, uncorrupted clinical decision making should be the measure of marketing
BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3358 (Published 03 August 2018) Cite this as: BMJ 2018;362:k3358- Alastair Matheson, independent consultant
- Toronto, Canada
- amatheson{at}outlook.com
Parker and colleagues discuss ethical drug marketing.1 One simple, potent yardstick for distinguishing acceptable from bad drug marketing derives from the perspective of the prescribing doctor.
When treatment decisions are made, the clinician’s reasoning should be free from interference, evidence based, cost aware, and appropriate to the needs and wishes of the patient. This basic principle of medicine leads to two fundamental marketing requirements.
Firstly, the only acceptable form of marketing should be the provision of information …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.